? ?Vonoprazan Fumarate (CAS 881681-01-2) | Pharmaceutical-Grade Potassium-Competitive Acid Blocker (P-CAB)? ?

?? ?Product Overview?

?Vonoprazan Fumarate? (CAS 881681-01-2) is a ?potassium-competitive acid blocker (P-CAB)? with the molecular formula ?C??H??FN?O?S? and molecular weight ?461.46?. This white to off-white crystalline powder (purity ≥98%) is clinically validated for treating ?acid-related gastrointestinal disorders?, including erosive esophagitis, gastric ulcers, and duodenal ulcers. It inhibits H+/K+-ATPase with rapid onset and prolonged efficacy, outperforming traditional proton pump inhibitors (PPIs).

?Key Functions?:

• Promotes healing of ?erosive esophagitis? and ?peptic ulcers?.

• Enhances ?Helicobacter pylori eradication? in combination therapy.

• Serves as a ?pharmaceutical intermediate? or reference standard for drug development.

?Target Industries?: Pharmaceutical manufacturing, biotechnology, and clinical research.

? ?Key Advantages?

?? ?Applications?

• ?Erosive Esophagitis?: Oral formulations for mucosal repair.

• ?Peptic Ulcer Therapy?: Effective for gastric and duodenal ulcers.

• ?H. pylori Eradication?: Used with antibiotics for dual-action protocols.

• ?Pharmaceutical Synthesis?: Intermediate for advanced P-CAB formulations.

?? ?Quality Assurance?

• ?Testing Standards?: Complies with ?USP/EP? pharmacopeial guidelines.

• ?Analytical Methods?: Validated via ?HPLC, NMR?, and ?mass spectrometry?.

• ?Packaging?: Customizable batches (1kg–25kg) with moisture-proof sealing.

?? ?Market Insights?

The global peptic ulcer therapeutics market is projected to grow at ?5.8% CAGR (2025–2030)?, driven by demand for non-PPI therapies. Asia-Pacific leads API production, with China dominating cost-efficient manufacturing.